BenchSci

Canvas Category Software : Special Purpose : Pharmaceutical

Primary Location Toronto, Ontario, Canada

Financial Status VC

BenchSci empowers scientists with the world’s most advanced biomedical AI to advance assets with fewer, more successful experiments,

Assembly Line

BenchSci Raises $95 Million Series D Funding to Enable Drug Discovery Innovation at Scale With its Groundbreaking AI Platform ASCEND

📅 Date: May 25, 2023

🔖 Topics: Funding Event

🏢 Organizations: BenchSci, Generation Investment Management

BenchSci, a world leader in AI solutions for preclinical life sciences research and development (R&D), today announced a $95 million (US $70 million) Series D funding round led by Generation Investment Management, with participation from existing investors iNovia Capital, TCV, Golden Ventures and F-Prime Capital. The most recent funding brings BenchSci’s total funds raised to $218 million (US $170 million).

The funds will be used to expand the company’s revolutionary AI drug discovery platform, ASCEND™ by BenchSci, which enables scientists to discover biological connections, dramatically reduce trial-and-error experimentation and uncover risks early. ASCEND users from BenchSci’s top 10 customers were able to uncover novel targets and disease indications in 22% of key projects and reduced unnecessary experimentation by 40%, contributing to a new era of more efficient, AI-driven drug discovery.